Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Seven Cleared to Sell Generic Plavix

By Drug Discovery Trends Editor | May 18, 2012

TRENTON, N.J. (AP) – Patients taking the popular blood thinner Plavix now have the option of getting a less-expensive pill, following the approval of the first generic versions in the United States.

That’s because the patent for Plavix, the world’s second-best-selling medicine, just expired. Plavix is taken by millions of people every day to prevent heart attacks and strokes, by preventing platelets in the blood from clumping together.

The Food and Drug Administration said it has given seven companies permission to sell generic Plavix, or clopidogrel, in the standard 75-milligram dose. The agency also gave four generic drugmakers approval to sell a 300-milligram dose of Plavix. That’s given as initial treatment to patients who have just had a heart attack.

Brand-name Plavix is marketed jointly by Bristol-Myers Squibb Co. and Sanofi SA. They’re now offering coupons giving a big discount off the brand price, which is about $200 per month.

Patients who sign up for the Plavix Choice Card program at www.plavix.com will get a 30-day supply for no more than $37 through the end of the year, if they are paying with cash or have private insurance. The program is not open to people covered by state or federal health programs, including Medicare and Medicaid, or to residents of Massachusetts, where such programs are prohibited.

Bristol-Myers and Sanofi had been splitting nearly $9 billion a year in revenue from Plavix the last several years, but that started declining in 2011 after the drug’s patent expired in several European countries and other major markets.

That revenue will decline more quickly with generic versions now available in the U.S., which accounts for close to half of all prescription drug sales globally.

According to the FDA, 75-milligram generic Plavix can now be sold by Apotex Corp., Aurobindo Pharma, Mylan Pharmaceuticals, Roxanne Laboratories, Sun Pharma, Teva Pharmaceuticals and Torrent Pharmaceuticals. The larger dose will be sold by Dr. Reddy’s Laboratories, Gate Pharmaceuticals, Mylan and Teva.

The generics should be available in pharmacies immediately. Among them, Walmart and Sam’s Club pharmacies nationwide will begin selling generic Plavix on May 19th, for about $40 a month or a $10 co-pay with insurance.

Date: May 18, 2012
Source: Associated Press

 


Filed Under: Drug Discovery

 

Related Articles Read More >

The FDA’s AI ambitions depend on better data practices
Researchers working in the clinical laboratory
Outpatient clinics are becoming critical Infrastructure for drug trials
SAS launches clinical trial analytics software built on its Viya cloud native analytics platform
Bayer’s Lynkuet approved by FDA for menopausal hot flashes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE